Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.

ABSTRACT:

Importance

In January 2023, the US Centers for Disease Control and Prevention and the US Food and Drug Administration noted a safety concern for ischemic stroke among adults aged 65 years or older who received the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 bivalent vaccine.

Objective

To evaluate stroke risk after administration of (1) either brand of the COVID-19 bivalent vaccine, (2) either brand of the COVID-19 bivalent plus a high-dose or adjuvanted influenza vaccine on the same day (concomitant administration), and (3) a high-dose or adjuvanted influenza vaccine.

Design, setting, and participants

Self-controlled case series including 11 001 Medicare beneficiaries aged 65 years or older who experienced stroke after receiving either brand of the COVID-19 bi

SUBMITTER: Lu Y 

PROVIDER: S-EPMC10951737 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature